{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:00:21Z","timestamp":1787162421193,"version":"build-2736575974"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["270650915"],"award-info":[{"award-number":["270650915"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["528968169"],"award-info":[{"award-number":["528968169"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Elterninitiative Kinderkrebsklinik e.V"},{"name":"Katharina-Hardt Foundation, Christiane und Claudia Hempel foundation, L\u00f6wenstern e.V."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Histone deacetylase 6 (HDAC6) has emerged as a promising therapeutic target in cancer due to its immunomodulatory effects. While its prognostic significance remains debated, we demonstrate that HDAC6 loss significantly impairs myeloid leukemia progression in vivo, despite having no functional impact on leukemia cell proliferation in vitro. Global proteome and secretome profiling of HDAC6-knockout (KO) cells revealed upregulation of several immune-related modulators, including RNase T2, a tumor suppressor known to modulate the tumor microenvironment. Notably, RNase T2 upregulation upon HDAC6 loss was observed in myeloid leukemia cells but not in lymphoblastic leukemia cells. Moreover, pharmacological inhibition of HDAC6 recapitulated this phenotype, leading to RNase T2 upregulation in myeloid leukemia cells. ATAC-seq revealed increased chromatin accessibility of RNase T2 following HDAC6 loss, highlighting a functionally epigenetic regulatory contribution. Further functional assays conducted in an immunocompetent setting, both ex vivo and in vivo, demonstrated that HDAC6 inhibition sensitized murine myeloid leukemia cells to broad CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell activation as evidenced by increased TNF\u03b1 and CD107a expression. Consistently, in a syngeneic murine model, HDAC6 inhibition restricted the growth of myeloid leukemia cells. Moreover, an extended drug screening analysis identified Cytarabine and Clofarabine as significantly synergizing with HDAC6 inhibitor (Ricolinostat) in myeloid leukemia cell lines and in patient-derived xenograft (PDX) cells, while showing limited synergy in lymphoid leukemia cell lines, PDX, or healthy control cells. These findings suggest that HDAC6 represents a promising therapeutic target in myeloid lineage-derived leukemia cells by simultaneously enhancing immune activation and increasing chemosensitivity.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-08541-3","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T13:54:45Z","timestamp":1772891685000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Epigenetic remodeling via HDAC6 inhibition amplifies anti-tumoral immune responses in myeloid leukemia cells"],"prefix":"10.1038","volume":"17","author":[{"given":"Julian","family":"Schliehe-Diecks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Wey","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Stachura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Schaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Kemkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Vasileiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"R\u00fcchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Brandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4799-5549","authenticated-orcid":false,"given":"Thomas","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adarsh","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9707-8191","authenticated-orcid":false,"given":"Stefanie","family":"Scheu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5775-4351","authenticated-orcid":false,"given":"Pilar M.","family":"Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Pastorczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Nebral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"St\u00fchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2455-2489","authenticated-orcid":false,"given":"Ute","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra A.","family":"Pandyra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6121-4737","authenticated-orcid":false,"given":"Arndt","family":"Borkhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6494-7744","authenticated-orcid":false,"given":"Sanil","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"key":"8541_CR1","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1182\/blood.2019004262","volume":"138","author":"HT Huang","year":"2021","unstructured":"Huang HT, Figueroa ME. Epigenetic deregulation in myeloid malignancies. Blood. 2021;138:613\u201324.","journal-title":"Blood"},{"key":"8541_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1127-7","volume":"19","author":"P Wang","year":"2020","unstructured":"Wang P, Wang Z, Liu J. Role of HDACs in normal and malignant hematopoiesis. Mol Cancer. 2020;19:5.","journal-title":"Mol Cancer"},{"key":"8541_CR3","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Cancer Genome Atlas Research N, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059\u201374.","journal-title":"N Engl J Med"},{"key":"8541_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.741746","volume":"11","author":"J Zhang","year":"2021","unstructured":"Zhang J, Gao X, Yu L. Roles of histone deacetylases in acute myeloid leukemia with fusion proteins. Front Oncol. 2021;11:741746.","journal-title":"Front Oncol"},{"key":"8541_CR5","doi-asserted-by":"publisher","first-page":"4851","DOI":"10.1002\/cncr.30949","volume":"123","author":"YM Abaza","year":"2017","unstructured":"Abaza YM, Kadia TM, Jabbour EJ, Konopleva MY, Borthakur G, Ferrajoli A, et al. Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. Cancer. 2017;123:4851\u20139.","journal-title":"Cancer"},{"key":"8541_CR6","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/ajh.26510","volume":"97","author":"L Pommert","year":"2022","unstructured":"Pommert L, Schafer ES, Malvar J, Gossai N, Florendo E, Pulakanti K, et al. Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed\/refractory AML: report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. Am J Hematol. 2022;97:613\u201322.","journal-title":"Am J Hematol"},{"key":"8541_CR7","doi-asserted-by":"publisher","first-page":"4800","DOI":"10.1002\/cncr.33156","volume":"126","author":"SE Karol","year":"2020","unstructured":"Karol SE, Cooper TM, Mead PE, Crews KR, Panetta JC, Alexander TB, et al. Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia. Cancer. 2020;126:4800\u20135.","journal-title":"Cancer"},{"key":"8541_CR8","doi-asserted-by":"publisher","first-page":"1794.","DOI":"10.3390\/cancers11111794","volume":"11","author":"E San Jose-Eneriz","year":"2019","unstructured":"San Jose-Eneriz E, Gimenez-Camino N, Agirre X, Prosper F. HDAC inhibitors in acute myeloid leukemia. Cancers. 2019;11:1794.","journal-title":"Cancers"},{"key":"8541_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-024-02108-8","volume":"29","author":"MS Hosseini","year":"2024","unstructured":"Hosseini MS, Sanaat Z, Akbarzadeh MA, Vaez-Gharamaleki Y, Akbarzadeh M. Histone deacetylase inhibitors for leukemia treatment: current status and future directions. Eur J Med Res. 2024;29:514.","journal-title":"Eur J Med Res"},{"key":"8541_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40264-018-0773-9","volume":"42","author":"RR Shah","year":"2019","unstructured":"Shah RR. Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology. Drug Saf. 2019;42:235\u201345.","journal-title":"Drug Saf"},{"key":"8541_CR11","doi-asserted-by":"publisher","first-page":"e26788","DOI":"10.1097\/MD.0000000000026788","volume":"100","author":"J Chen","year":"2021","unstructured":"Chen J, Ren JJ, Cai J, Wang X. Efficacy and safety of HDACIs in the treatment of metastatic or unresectable renal cell carcinoma with a clear cell phenotype: a systematic review and meta-analysis. Medicine. 2021;100:e26788.","journal-title":"Medicine"},{"key":"8541_CR12","doi-asserted-by":"publisher","first-page":"505","DOI":"10.4155\/fmc.12.3","volume":"4","author":"BE Gryder","year":"2012","unstructured":"Gryder BE, Sodji QH, Oyelere AK. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem. 2012;4:505\u201324.","journal-title":"Future Med Chem"},{"key":"8541_CR13","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3389\/fonc.2018.00092","volume":"8","author":"A Suraweera","year":"2018","unstructured":"Suraweera A, O\u2019Byrne KJ, Richard DJ. Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi. Front Oncol. 2018;8:92.","journal-title":"Front Oncol"},{"key":"8541_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113825","volume":"226","author":"M Zhou","year":"2021","unstructured":"Zhou M, Yuan M, Zhang M, Lei C, Aras O, Zhang X, et al. Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy. Eur J Med Chem. 2021;226:113825.","journal-title":"Eur J Med Chem"},{"key":"8541_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-018-0654-9","volume":"11","author":"T Li","year":"2018","unstructured":"Li T, Zhang C, Hassan S, Liu X, Song F, Chen K, et al. Histone deacetylase 6 in cancer. J Hematol Oncol. 2018;11:111.","journal-title":"J Hematol Oncol"},{"key":"8541_CR16","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/417455a","volume":"417","author":"C Hubbert","year":"2002","unstructured":"Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, et al. HDAC6 is a microtubule-associated deacetylase. Nature. 2002;417:455\u20138.","journal-title":"Nature"},{"key":"8541_CR17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.molcel.2007.05.033","volume":"27","author":"X Zhang","year":"2007","unstructured":"Zhang X, Yuan Z, Zhang Y, Yong S, Salas-Burgos A, Koomen J, et al. HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol Cell. 2007;27:197\u2013213.","journal-title":"Mol Cell"},{"key":"8541_CR18","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.molcel.2005.04.021","volume":"18","author":"JJ Kovacs","year":"2005","unstructured":"Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell. 2005;18:601\u20137.","journal-title":"Mol Cell"},{"key":"8541_CR19","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.canlet.2017.01.033","volume":"391","author":"HW Ryu","year":"2017","unstructured":"Ryu HW, Shin DH, Lee DH, Choi J, Han G, Lee KY, et al. HDAC6 deacetylates p53 at lysines 381\/382 and differentially coordinates p53-induced apoptosis. Cancer Lett. 2017;391:162\u201371.","journal-title":"Cancer Lett"},{"key":"8541_CR20","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1128\/MCB.01154-06","volume":"28","author":"Y Zhang","year":"2008","unstructured":"Zhang Y, Kwon S, Yamaguchi T, Cubizolles F, Rousseaux S, Kneissel M, et al. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol. 2008;28:1688\u2013701.","journal-title":"Mol Cell Biol"},{"key":"8541_CR21","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1182\/bloodadvances.2018020065","volume":"2","author":"K Maharaj","year":"2018","unstructured":"Maharaj K, Powers JJ, Achille A, Deng S, Fonseca R, Pabon-Saldana M, et al. Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia. Blood Adv. 2018;2:3012\u201324.","journal-title":"Blood Adv"},{"key":"8541_CR22","doi-asserted-by":"publisher","first-page":"318.","DOI":"10.3390\/cancers12020318","volume":"12","author":"H Losson","year":"2020","unstructured":"Losson H, Schnekenburger M, Dicato M, Diederich M. HDAC6-an emerging target against chronic myeloid leukemia?. Cancers. 2020;12:318.","journal-title":"Cancers"},{"key":"8541_CR23","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1038\/sj.leu.2403910","volume":"19","author":"CA Bradbury","year":"2005","unstructured":"Bradbury CA, Khanim FL, Hayden R, Bunce CM, White DA, Drayson MT, et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia. 2005;19:1751\u20139.","journal-title":"Leukemia"},{"key":"8541_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-020-00839-z","volume":"12","author":"M Lernoux","year":"2020","unstructured":"Lernoux M, Schnekenburger M, Losson H, Vermeulen K, Hahn H, Gerard D, et al. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL\/MYC-signaling: effect on imatinib resistance and stem cells. Clin Epigenetics. 2020;12:69.","journal-title":"Clin Epigenetics"},{"key":"8541_CR25","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.yexcr.2018.07.017","volume":"370","author":"OA Bamodu","year":"2018","unstructured":"Bamodu OA, Kuo KT, Yuan LP, Cheng WH, Lee WH, Ho YS, et al. HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR\/ABL1. Exp Cell Res. 2018;370:519\u201330.","journal-title":"Exp Cell Res"},{"key":"8541_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106378","volume":"183","author":"A Pezzotta","year":"2022","unstructured":"Pezzotta A, Gentile I, Genovese D, Totaro MG, Battaglia C, Leung AY, et al. HDAC6 inhibition decreases leukemic stem cell expansion driven by Hedgehog hyperactivation by restoring primary ciliogenesis. Pharm Res. 2022;183:106378.","journal-title":"Pharm Res"},{"key":"8541_CR27","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.leukres.2012.02.026","volume":"36","author":"B Hackanson","year":"2012","unstructured":"Hackanson B, Rimmele L, Benkisser M, Abdelkarim M, Fliegauf M, Jung M, et al. HDAC6 as a target for antileukemic drugs in acute myeloid leukemia. Leuk Res. 2012;36:1055\u201362.","journal-title":"Leuk Res"},{"key":"8541_CR28","doi-asserted-by":"publisher","first-page":"10339","DOI":"10.1021\/acs.jmedchem.9b01888","volume":"63","author":"N Re\u00dfing","year":"2020","unstructured":"Re\u00dfing N, S\u00f6nnichsen M, Osko JD, Sch\u00f6ler A, Schliehe-Diecks J, Skerhut A, et al. Multicomponent synthesis, binding mode, and structure-activity relationship of selective histone deacetylase 6 (HDAC6) inhibitors with bifurcated capping groups. J Med Chem. 2020;63:10339\u201351.","journal-title":"J Med Chem"},{"key":"8541_CR29","doi-asserted-by":"publisher","first-page":"15457","DOI":"10.1021\/acs.jmedchem.2c01418","volume":"65","author":"N Re\u00dfing","year":"2022","unstructured":"Re\u00dfing N, Schliehe-Diecks J, Watson PR, S\u00f6nnichsen M, Cragin AD, Sch\u00f6ler A, et al. Development of fluorinated peptoid-based histone deacetylase (HDAC) inhibitors for therapy-resistant acute leukemia. J Med Chem. 2022;65:15457\u201372.","journal-title":"J Med Chem"},{"key":"8541_CR30","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/ijc.32169","volume":"145","author":"Y Depetter","year":"2019","unstructured":"Depetter Y, Geurs S, De Vreese R, Goethals S, Vandoorn E, Laevens A, et al. Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models. Int J Cancer. 2019;145:735\u201347.","journal-title":"Int J Cancer"},{"key":"8541_CR31","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nm.4439","volume":"24","author":"H Bolouri","year":"2018","unstructured":"Bolouri H, Farrar JE, Triche T Jr, Ries RE, Lim EL, Alonzo TA, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2018;24:103\u201312.","journal-title":"Nat Med"},{"key":"8541_CR32","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s11357-023-00742-4","volume":"45","author":"B Gyorffy","year":"2023","unstructured":"Gyorffy B. Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer. Geroscience. 2023;45:1889\u201398.","journal-title":"Geroscience"},{"key":"8541_CR33","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1158\/1078-0432.CCR-16-2526","volume":"23","author":"DT Vogl","year":"2017","unstructured":"Vogl DT, Raje N, Jagannath S, Richardson P, Hari P, Orlowski R, et al. Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. Clin Cancer Res. 2017;23:3307\u201315.","journal-title":"Clin Cancer Res"},{"key":"8541_CR34","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S1470-2045(16)30375-8","volume":"17","author":"AJ Yee","year":"2016","unstructured":"Yee AJ, Bensinger WI, Supko JG, Voorhees PM, Berdeja JG, Richardson PG, et al. Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. Lancet Oncol. 2016;17:1569\u201378.","journal-title":"Lancet Oncol"},{"key":"8541_CR35","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.cell.2009.06.049","volume":"138","author":"Z Wang","year":"2009","unstructured":"Wang Z, Zang C, Cui K, Schones DE, Barski A, Peng W, et al. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell. 2009;138:1019\u201331.","journal-title":"Cell"},{"key":"8541_CR36","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S0092-8674(03)00939-5","volume":"115","author":"Y Kawaguchi","year":"2003","unstructured":"Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell. 2003;115:727\u201338.","journal-title":"Cell"},{"key":"8541_CR37","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1083\/jcb.201804165","volume":"218","author":"R Wang","year":"2019","unstructured":"Wang R, Tan J, Chen T, Han H, Tian R, Tan Y, et al. ATP13A2 facilitates HDAC6 recruitment to lysosome to promote autophagosome-lysosome fusion. J Cell Biol. 2019;218:267\u201384.","journal-title":"J Cell Biol"},{"key":"8541_CR38","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1182\/blood-2016-08-736066","volume":"130","author":"M Bobrowicz","year":"2017","unstructured":"Bobrowicz M, Dwojak M, Pyrzynska B, Stachura J, Muchowicz A, Berthel E, et al. HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies. Blood. 2017;130:1628\u201338.","journal-title":"Blood"},{"key":"8541_CR39","doi-asserted-by":"publisher","first-page":"2160.","DOI":"10.3390\/biomedicines11082160","volume":"11","author":"P Campomenosi","year":"2023","unstructured":"Campomenosi P, Mortara L, Bassani B, Valli R, Porta G, Bruno A. The potential role of the T2 ribonucleases in TME-based cancer therapy. Biomedicines. 2023;11:2160.","journal-title":"Biomedicines"},{"key":"8541_CR40","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.3389\/fimmu.2020.01554","volume":"11","author":"L Wu","year":"2020","unstructured":"Wu L, Xu Y, Zhao H, Li Y. RNase T2 in inflammation and cancer: immunological and biological views. Front Immunol. 2020;11:1554.","journal-title":"Front Immunol"},{"key":"8541_CR41","doi-asserted-by":"publisher","first-page":"8140","DOI":"10.1073\/pnas.1222079110","volume":"110","author":"F Acquati","year":"2013","unstructured":"Acquati F, Lualdi M, Bertilaccio S, Monti L, Turconi G, Fabbri M, et al. Loss of function of Ribonuclease T2, an ancient and phylogenetically conserved RNase, plays a crucial role in ovarian tumorigenesis. Proc Natl Acad Sci USA. 2013;110:8140\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8541_CR42","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.3389\/fimmu.2019.02587","volume":"10","author":"F Acquati","year":"2019","unstructured":"Acquati F, Mortara L, De Vito A, Baci D, Albini A, Cippitelli M, et al. Innate immune response regulation by the human RNASET2 tumor suppressor gene. Front Immunol. 2019;10:2587.","journal-title":"Front Immunol"},{"key":"8541_CR43","first-page":"e54270.","volume":"116","author":"A Mopin","year":"2016","unstructured":"Mopin A, Driss V, Brinster C. A detailed protocol for characterizing the murine C1498 cell line and its associated leukemia mouse model. J Vis Exp. 2016;116:e54270.","journal-title":"J Vis Exp"},{"key":"8541_CR44","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0022-1759(03)00265-5","volume":"281","author":"MR Betts","year":"2003","unstructured":"Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods. 2003;281:65\u201378.","journal-title":"J Immunol Methods"},{"key":"8541_CR45","doi-asserted-by":"publisher","first-page":"20003","DOI":"10.1073\/pnas.1013754107","volume":"107","author":"M Namdar","year":"2010","unstructured":"Namdar M, Perez G, Ngo L, Marks PA. Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proc Natl Acad Sci USA. 2010;107:20003\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8541_CR46","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-024-08248-5","volume":"637","author":"J Jin","year":"2025","unstructured":"Jin J, Meng T, Yu Y, Wu S, Jiao CC, Song S, et al. Human HDAC6 senses valine abundancy to regulate DNA damage. Nature. 2025;637:215\u201323.","journal-title":"Nature"},{"key":"8541_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.10","volume":"2","author":"A Khwaja","year":"2016","unstructured":"Khwaja A, Bjorkholm M, Gale RE, Levine RL, Jordan CT, Ehninger G, et al. Acute myeloid leukaemia. Nat Rev Dis Prim. 2016;2:16010.","journal-title":"Nat Rev Dis Prim"},{"key":"8541_CR48","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41588-023-01640-3","volume":"56","author":"M Umeda","year":"2024","unstructured":"Umeda M, Ma J, Westover T, Ni Y, Song G, Maciaszek JL, et al. A new genomic framework to categorize pediatric acute myeloid leukemia. Nat Genet. 2024;56:281\u201393.","journal-title":"Nat Genet"},{"key":"8541_CR49","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/ajh.27625","volume":"100","author":"S Shimony","year":"2025","unstructured":"Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2025 update on diagnosis, risk-stratification, and management. Am J Hematol. 2025;100:860\u201391.","journal-title":"Am J Hematol"},{"key":"8541_CR50","doi-asserted-by":"publisher","first-page":"5938","DOI":"10.1182\/blood-2010-11-321414","volume":"118","author":"Z Hu","year":"2011","unstructured":"Hu Z, Van Rooijen N, Yang YG. Macrophages prevent human red blood cell reconstitution in immunodeficient mice. Blood. 2011;118:5938\u201346.","journal-title":"Blood"},{"key":"8541_CR51","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/emboj.2009.405","volume":"29","author":"J-Y Lee","year":"2010","unstructured":"Lee J-Y, Koga H, Kawaguchi Y, Tang W, Wong E, Gao Y-S, et al. HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. EMBO J. 2010;29:969\u201380.","journal-title":"EMBO J"},{"key":"8541_CR52","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1159\/000437208","volume":"15","author":"JY Lee","year":"2015","unstructured":"Lee JY, Kawaguchi Y, Li M, Kapur M, Choi SJ, Kim HJ, et al. Uncoupling of protein aggregation and neurodegeneration in a mouse amyotrophic lateral sclerosis model. Neurodegener Dis. 2015;15:339\u201349.","journal-title":"Neurodegener Dis"},{"key":"8541_CR53","doi-asserted-by":"publisher","first-page":"40282","DOI":"10.1074\/jbc.M508786200","volume":"280","author":"A Iwata","year":"2005","unstructured":"Iwata A, Riley BE, Johnston JA, Kopito RR. HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J Biol Chem. 2005;280:40282\u201392.","journal-title":"J Biol Chem"},{"key":"8541_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.605609","volume":"8","author":"Y Zhan","year":"2020","unstructured":"Zhan Y, Wang H, Zhang L, Pei F, Chen Z. HDAC6 regulates the fusion of autophagosome and lysosome to involve in odontoblast differentiation. Front Cell Dev Biol. 2020;8:605609.","journal-title":"Front Cell Dev Biol"},{"key":"8541_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1216548","volume":"14","author":"M Qu","year":"2023","unstructured":"Qu M, Zhang H, Cheng P, Wubshet AK, Yin X, Wang X, et al. Histone deacetylase 6\u2019s function in viral infection, innate immunity, and disease: latest advances. Front Immunol. 2023;14:1216548.","journal-title":"Front Immunol"},{"key":"8541_CR56","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/s41419-022-05335-1","volume":"13","author":"G Xu","year":"2022","unstructured":"Xu G, Niu L, Wang Y, Yang G, Zhu X, Yao Y, et al. HDAC6-dependent deacetylation of TAK1 enhances sIL-6R release to promote macrophage M2 polarization in colon cancer. Cell Death Dis. 2022;13:888.","journal-title":"Cell Death Dis"},{"key":"8541_CR57","doi-asserted-by":"publisher","first-page":"eaaw8412.","DOI":"10.1126\/scitranslmed.aaw8412","volume":"11","author":"A Lin","year":"2019","unstructured":"Lin A, Giuliano CJ, Palladino A, John KM, Abramowicz C, Yuan ML. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci Transl Med. 2019;11:eaaw8412.","journal-title":"Sci Transl Med"},{"key":"8541_CR58","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s43018-023-00582-3","volume":"4","author":"G Medard","year":"2023","unstructured":"Medard G, Sheltzer JM. Ricolinostat is not a highly selective HDAC6 inhibitor. Nat Cancer. 2023;4:807\u20138.","journal-title":"Nat Cancer"},{"key":"8541_CR59","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adp3687","volume":"10","author":"D Kovalovsky","year":"2024","unstructured":"Kovalovsky D, Noonepalle S, Suresh M, Kumar D, Berrigan M, Gajendran N, et al. The HDAC6 inhibitor AVS100 (SS208) induces a pro-inflammatory tumor microenvironment and potentiates immunotherapy. Sci Adv. 2024;10:eadp3687.","journal-title":"Sci Adv"},{"key":"8541_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fragi.2021.809539","volume":"2","author":"J Jin","year":"2021","unstructured":"Jin J, Zhang H, Weyand CM, Goronzy JJ. Lysosomes in T cell immunity and aging. Front Aging. 2021;2:809539.","journal-title":"Front Aging"},{"key":"8541_CR61","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1158\/2159-8290.CD-16-1020","volume":"7","author":"DO Adeegbe","year":"2017","unstructured":"Adeegbe DO, Liu Y, Lizotte PH, Kamihara Y, Aref AR, Almonte C, et al. Synergistic immunostimulatory effects and therapeutic benefit of combined histone deacetylase and bromodomain inhibition in non-small cell lung cancer. Cancer Discov. 2017;7:852\u201367.","journal-title":"Cancer Discov"},{"key":"8541_CR62","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1038\/s41375-018-0062-8","volume":"32","author":"J Bae","year":"2018","unstructured":"Bae J, Hideshima T, Tai YT, Song Y, Richardson P, Raje N, et al. Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors. Leukemia. 2018;32:1932\u201347.","journal-title":"Leukemia"},{"key":"8541_CR63","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41419-023-06337-3","volume":"14","author":"M Vogt","year":"2023","unstructured":"Vogt M, Dienstbier N, Schliehe-Diecks J, Scharov K, Tu JW, Gebing P, et al. Co-targeting HSP90 alpha and CDK7 overcomes resistance against HSP90 inhibitors in BCR-ABL1+ leukemia cells. Cell Death Dis. 2023;14:799.","journal-title":"Cell Death Dis"},{"key":"8541_CR64","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1182\/blood-2017-10-810986","volume":"132","author":"S Bhatia","year":"2018","unstructured":"Bhatia S, Diedrich D, Frieg B, Ahlert H, Stein S, Bopp B, et al. Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response. Blood. 2018;132:307\u201320.","journal-title":"Blood"},{"key":"8541_CR65","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1158\/2643-3230.BCD-19-0059","volume":"2","author":"R Flumann","year":"2021","unstructured":"Flumann R, Rehkamper T, Nieper P, Pfeiffer P, Holzem A, Klein S, et al. An autochthonous mouse model of Myd88- and BCL2-driven diffuse large B-cell lymphoma reveals actionable molecular vulnerabilities. Blood Cancer Discov. 2021;2:70\u201391.","journal-title":"Blood Cancer Discov"},{"key":"8541_CR66","doi-asserted-by":"publisher","first-page":"4997","DOI":"10.1182\/bloodadvances.2023011145","volume":"8","author":"P Gebing","year":"2024","unstructured":"Gebing P, Loizou S, Hansch S, Schliehe-Diecks J, Spory L, Stachura P, et al. A brain organoid\/ALL coculture model reveals the AP-1 pathway as critically associated with CNS involvement of BCP-ALL. Blood Adv. 2024;8:4997\u20135011.","journal-title":"Blood Adv"},{"key":"8541_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01833-8","volume":"22","author":"P Stachura","year":"2023","unstructured":"Stachura P, Liu W, Xu HC, Wlodarczyk A, Stencel O, Pandey P, et al. Unleashing T cell anti-tumor immunity: new potential for 5-Nonloxytryptamine as an agent mediating MHC-I upregulation in tumors. Mol Cancer. 2023;22:136.","journal-title":"Mol Cancer"},{"key":"8541_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1110522","volume":"14","author":"P Stachura","year":"2023","unstructured":"Stachura P, Stencel O, Lu Z, Borkhardt A, Pandyra AA. Arenaviruses: old viruses present new solutions for cancer therapy. Front Immunol. 2023;14:1110522.","journal-title":"Front Immunol"},{"key":"8541_CR69","doi-asserted-by":"publisher","unstructured":"DepMap, Broad (2024). DepMap 24Q4 Public. Figshare+. Dataset. https:\/\/doi.org\/10.25452\/figshare.plus.27993248.v1.","DOI":"10.25452\/figshare.plus.27993248.v1"},{"key":"8541_CR70","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1158\/2159-8290.CD-20-1230","volume":"11","author":"C McLeod","year":"2021","unstructured":"McLeod C, Gout AM, Zhou X, Thrasher A, Rahbarinia D, Brady SW, et al. St. Jude Cloud: a pediatric cancer genomic data-sharing ecosystem. Cancer Discov. 2021;11:1082\u201399.","journal-title":"Cancer Discov"},{"key":"8541_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-06841-0","volume":"12","author":"B Dwivedi","year":"2022","unstructured":"Dwivedi B, Mumme H, Satpathy S, Bhasin SS, Bhasin M. Survival Genie, a web platform for survival analysis across pediatric and adult cancers. Sci Rep. 2022;12:3069.","journal-title":"Sci Rep"},{"key":"8541_CR72","doi-asserted-by":"publisher","first-page":"6388","DOI":"10.1073\/pnas.1219651110","volume":"110","author":"Y Drier","year":"2013","unstructured":"Drier Y, Sheffer M, Domany E. Pathway-based personalized analysis of cancer. Proc Natl Acad Sci USA. 2013;110:6388\u201393.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8541_CR73","doi-asserted-by":"publisher","first-page":"10934","DOI":"10.1093\/nar\/gkad841","volume":"51","author":"S Muller-Dott","year":"2023","unstructured":"Muller-Dott S, Tsirvouli E, Vazquez M, Ramirez Flores RO, Badia IMP, Fallegger R, et al. Expanding the coverage of regulons from high-confidence prior knowledge for accurate estimation of transcription factor activities. Nucleic Acids Res. 2023;51:10934\u201349.","journal-title":"Nucleic Acids Res"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08541-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08541-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08541-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T20:02:38Z","timestamp":1774987358000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08541-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8541"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08541-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.05.30.654805","asserted-by":"object"}]},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,7]]},"assertion":[{"value":"3 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Patient samples were collected after obtaining written informed consent in accordance with the Declaration of Helsinki and with approval from the respective local ethics committees of the Medical Faculty at University Hospital D\u00fcsseldorf (Germany), the Medical University of Vienna (Austria), and the Medical University of Lodz (Poland). All animal experiments were performed in compliance with institutional and governmental regulations and were approved by the responsible regulatory authority (Landesamt f\u00fcr Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen, LANUV, NRW, Germany) and the animal research institute (ZETT) of Heinrich Heine University D\u00fcsseldorf.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"300"}}